Research company Oncopeptides intends to carry out a directed share issue of SEK 100 million, according to a press release.
The company has retained ABG Sundal Collier to investigate the conditions for carrying out the directed share issue.
Oncopeptides’ largest shareholder, Healthcap VIII, has indicated its intention to subscribe for shares in the directed share issue corresponding to SEK 10 million.
The subscription price will be determined through an accelerated bookbuilding process, which begins immediately after the publication of this press release and is expected to be completed before trading on Nasdaq Stockholm begins tomorrow, 14 October.
